Last checked at 24 Sep 2020 09:36
PDMR Dealings / Market Share sale
Oxford, UK - 24 September 2020: Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, was informed that on 22 September 2020, that Dr. Kyriacos Mitrophanous, Chief Scientific Officer of the Group, exercised 9,255 DBP (2016) options at nil cost, exercised 19,623 LTIP (2015) options at nil cost and sold all of the resulting shares at 837p. He also exercised 6,547 LTIP (2014) options at 50p and sold all the resulting shares at 837p. Following these transactions Dr. Mitrophanous holds 172,476 options and no shares in the Company.
The issued share capital of the Group is 82,185,673 ordinary 50p shares.
The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares sold.
1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||||||
a) | Name | Kyriacos Mitrophanous | ||||||||
2. | Reason for the notification | |||||||||
a) | Position/status | Chief Scientific Officer
| ||||||||
b) | Initial notification/ amendment | Initial Notification | ||||||||
3. | Details of the Issuer | |||||||||
a) | Name | Oxford BioMedica plc | ||||||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||||||
b) | Nature of the transaction | Exercise of options | ||||||||
c) | Currency | GBP - British pound | ||||||||
d) | Price(s) and volumes(s) |
| ||||||||
e) | Aggregated information - Aggregate volume
- Price
- Aggregated total
|
35,425
£0.092
£3,273.50 | ||||||||
f) | Date of the transaction | 2020-09-22 | ||||||||
g) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||||||
1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||||||
a) | Name | Kyriacos Mitrophanous | ||||||||
2. | Reason for the notification | |||||||||
a) | Position/status | Chief Business Officer
| ||||||||
b) | Initial notification/ amendment | Initial Notification | ||||||||
3. | Details of the Issuer | |||||||||
a) | Name | Oxford BioMedica plc | ||||||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||||||
b) | Nature of the transaction | Disposal | ||||||||
c) | Currency | GBP - British pound | ||||||||
d) | Price(s) and volumes(s) |
| ||||||||
e) | Aggregated information - Aggregate volume
- Price
- Aggregated total
|
35,425
£8.37
£296.507.25 | ||||||||
f) | Date of the transaction | 2020-09-22 | ||||||||
g) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||||||
-Ends-
For further information, please contact: |
|
Oxford Biomedica plc: Natalie Walter, Company Secretary |
Tel: +44 (0)1865 783 000 |
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a three-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 580 people. Further information is available at www.oxb.com